+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Dilated Cardiomyopathy Market by Drug Class Inhibitors, Treatment Type, Route of Administration, Distribution Channel, and By Region

  • PDF Icon

    Report

  • 200 Pages
  • March 2024
  • Region: Global
  • Erevna Healthcare
  • ID: 5941913
The global dilated cardiomyopathy market size was estimated to be USD 422.6 million in 2023 and is expected to reach USD 652.0 million by 2034 with a CAGR of 4.02% during the forecast period 2024-2034. The rising prevalence of heart failure, growing awareness of DCM, rising government initiatives, development of novel therapies, technological advancements, and collaborations and partnerships will drive the market growth.

Heart failure is mostly caused by DCM, which accounts for 30-40% of cases worldwide. Numerous reasons, such as aging populations, unhealthy lifestyles, and the increased burden of chronic illnesses like diabetes and obesity, are to blame for the rising prevalence of heart failure. For instance, Novartis AG presented promising Phase 3 results in December 2023 on the reduction of hospitalizations for heart failure among patients with preserved ejection fraction (HFpEF) and DCM. The medication Entresto (sacubitril/valsartan).

By drug class, the angiotensin-converting enzyme (ACE) inhibitors segment accounted for the highest revenue-grossing segment in the global dilated cardiomyopathy market in 2023 owing to the widespread adoption of ACE inhibitors as a primary therapeutic intervention for Dilated Cardiomyopathy. This class of medications, including widely prescribed drugs like enalapril, lisinopril, and ramipril, demonstrated efficacy in managing the condition by inhibiting the angiotensin-converting enzyme, thereby reducing the production of angiotensin II. For instance, in August 2023, Pfizer Inc. presented findings at the European Society of Cardiology Congress that suggested Tafamidis (Vyndaqel) may be able to improve exercise capacity and quality of life in individuals with DCM. Additionally, the angiotensin II receptor blockers segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing recognition of their efficacy and tolerability in the management of Dilated Cardiomyopathy, coupled with a rising preference for alternative therapeutic options.

By treatment type, the medication segment accounted for the highest revenue-grossing segment in the global dilated cardiomyopathy market in 2023 owing to the increased demand for a diverse range of pharmaceutical interventions, including beta-blockers, diuretics, anticoagulants, and other medications, for the comprehensive management of Dilated Cardiomyopathy. For instance, in August 2023, the Bristol Myers Squibb Company started a Phase 2 study for BMS-986158, a novel investigational small molecule that may possibly be used to treat DCM. The trial was initiated for the treatment of heart failure with preserved ejection fraction (HFpEF). Additionally, the implantable devices segment is predicted to grow at the fastest CAGR during the forecast period owing to the increased adoption of advanced and innovative technologies for the management of Dilated Cardiomyopathy, with implantable devices offering significant therapeutic benefits.

By route of administration, the oral segment accounted for the highest revenue-grossing segment in the global dilated cardiomyopathy market in 2023 owing to the convenience and widespread patient acceptance of oral medications, particularly in the form of tablets and capsules, for the management of Dilated Cardiomyopathy. For instance, in July 2023, MK-6776, a new experimental inhibitor of sGC stimulator (sGC-ST), presented encouraging Phase 2 results that suggested the treatment of HFpEF and maybe DCM. Additionally, the parenteral segment is predicted to grow at the fastest CAGR during the forecast period owing to the increased focus on rapid and targeted drug delivery, especially in acute and critical situations associated with Dilated Cardiomyopathy, where parenteral administration offers quicker onset of action and precise dosage control.

By distribution channel, the hospital pharmacy segment accounted for the highest revenue-grossing segment in the global dilated cardiomyopathy market in 2023 owing to the central role of hospitals in the diagnosis, treatment, and management of Dilated Cardiomyopathy, with hospital pharmacies serving as key distribution points for a wide range of medications and therapeutic interventions. For instance, Johnson & Johnson announced in April 2023 the start of the Phase 2b study of ARNI-1901, a next-generation ARNI candidate with potential uses in DCM, for the treatment of heart failure. Additionally, the online pharmacies segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing trend of digital healthcare adoption, improved accessibility, and the convenience offered by online pharmacies in catering to the evolving needs of patients seeking Dilated Cardiomyopathy medications.

North American region is anticipated to have the highest revenue share during the forecast period owing to the high prevalence of Dilated Cardiomyopathy, well-established healthcare infrastructure, and a robust research and development landscape, facilitating the continuous introduction of advanced therapeutic interventions and technologies. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rising prevalence of cardiovascular diseases, including Dilated Cardiomyopathy, a rapidly expanding geriatric population, and increasing healthcare infrastructure and investments. For instance, in September 2023, Amgen Inc. presented findings at the European Society of Cardiology Congress that suggested omecamtiv mecarbil (Myocampa) may have the potential to improve cardiac function and exercise capacity in individuals with DCM.

This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.

Report Scope:

  • Base Year: 2023
  • Forecast Period: 2024-2034
  • Study Coverage
  • Market Forecast by Drug Class, Treatment Type, Route of Administration, and Distribution Channel
  • Market Forecast for 5 Regions and 17+ Countries
  • North America (U.S. and Canada)
  • Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
  • Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
  • Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
  • MEA (South Africa, GCC, Rest of MEA)
  • Exhaustive Company Profiles of the Top 10+ Major Market Players
  • 20% Free Customization Available to Meet Your Exact Requirement.

Segmentation: Dilated Cardiomyopathy Market Report 2023 - 2034

Dilated Cardiomyopathy Market Analysis & Forecast by Drug Class 2023 - 2034 (Revenue USD Mn)

  • Angiotensin-converting enzyme (ACE) Inhibitors
  • Beta-blockers
  • Aldosterone antagonists
  • Angiotensin II Receptor Blockers
  • Others

Dilated Cardiomyopathy Market Analysis & Forecast by Treatment Type 2023 - 2034 (Revenue USD Mn)

  • Medication
  • Implantable Devices
  • Heart Pumps
  • Cardioverter-Defibrillators
  • Others

Dilated Cardiomyopathy Market Analysis & Forecast by Route of Administration 2023 - 2034 (Revenue USD Mn)

  • Oral
  • Parenteral
  • Others

Dilated Cardiomyopathy Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Mn)

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacies
  • Others

Dilated Cardiomyopathy Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Mn)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of LATAM
  • Middle East & Africa
  • South Africa
  • GCC
  • Rest of MEA

Table of Contents

1. Research Methodology
1.1. Study Objectives
1.2. Study Scope
1.3. Research Assumptions
1.4. Research Framework
2. Introduction
2.1. Market Definition
2.2. Global Dilated Cardiomyopathy Market Overview
3. Executive Summary
4. Market Environment Analysis
4.1. Porter’s 5 Forces Analysis
4.2. PESTEL Analysis
4.3. SWOT Analysis
5. Market Dynamics
5.1. Drivers Analysis
5.2. Restraints Analysis
5.3. Opportunities Analysis
5.4. Threats Analysis
5.5. Trend Analysis
6. COVID-19 Impact Analysis
7. Dilated Cardiomyopathy Market: Drug Class Estimates & Trend Analysis
7.1. Drug Class Segment Opportunity Analysis
7.2. Angiotensin-converting enzyme (ACE) Inhibitors
7.2.1. Angiotensin-converting enzyme (ACE) Inhibitors Market Analysis & Forecast, 2023-2034 (Revenue, USD Mn)
7.3. Beta-blockers
7.3.1. Beta-blockers Market Analysis & Forecast, 2023-2034 (Revenue, USD Mn)
7.4. Aldosterone antagonists
7.4.1. Aldosterone antagonists Market Analysis & Forecast, 2023-2034 (Revenue, USD Mn)
7.5. Angiotensin II Receptor Blockers
7.5.1. Angiotensin II Receptor Blockers Market Analysis & Forecast, 2023-2034 (Revenue, USD Mn)
7.6. Others
7.6.1. Others Market Analysis & Forecast, 2023-2034 (Revenue, USD Mn)
8. Dilated Cardiomyopathy Market: Treatment Type Estimates & Trend Analysis
8.1. Treatment Type Segment Opportunity Analysis
8.2. Medication
8.2.1. Medication Market Analysis & Forecast, 2023-2034 (Revenue, USD Mn)
8.3. Implantable Devices
8.3.1. Implantable Devices Market Analysis & Forecast, 2023-2034 (Revenue, USD Mn)
8.4. Heart Pumps
8.4.1. Heart Pumps Market Analysis & Forecast, 2023-2034 (Revenue, USD Mn)
8.5. Cardioverter-Defibrillators
8.5.1. Cardioverter-Defibrillators Market Analysis & Forecast, 2023-2034 (Revenue, USD Mn)
8.6. Others
8.6.1. Others Market Analysis & Forecast, 2023-2034 (Revenue, USD Mn)
9. Dilated Cardiomyopathy Market: Route of Administration Estimates & Trend Analysis
9.1. Route of Administration Segment Opportunity Analysis
9.2. Oral
9.2.1. Oral Market Analysis & Forecast, 2023-2034 (Revenue, USD Mn)
9.3. Parenteral
9.3.1. Parenteral Market Analysis & Forecast, 2023-2034 (Revenue, USD Mn)
9.4. Others
9.4.1. Others Market Analysis & Forecast, 2023-2034 (Revenue, USD Mn)
10. Dilated Cardiomyopathy Market: Distribution Channel Estimates & Trend Analysis
10.1. Distribution Channel Segment Opportunity Analysis
10.2. Hospital Pharmacy
10.2.1. Hospital Pharmacy Market Analysis & Forecast, 2023-2034 (Revenue, USD Mn)
10.3. Retail Pharmacy
10.3.1. Retail Pharmacy Market Analysis & Forecast, 2023-2034 (Revenue, USD Mn)
10.4. Online Pharmacies
10.4.1. Online Pharmacies Market Analysis & Forecast, 2023-2034 (Revenue, USD Mn)
10.5. Others
10.5.1. Others Market Analysis & Forecast, 2023-2034 (Revenue, USD Mn)
11. Regional Market Analysis
11.1. Regional Market Opportunity Analysis
12. North America Dilated Cardiomyopathy Market
12.1. North America Dilated Cardiomyopathy Market
12.1.1. North America Dilated Cardiomyopathy Market Size and Forecast, 2023-2034 (Revenue USD Mn)
12.1.2. North America Dilated Cardiomyopathy Market Size and Forecast, By Country, 2023-2034 (Revenue USD Mn)
12.1.3. North America Dilated Cardiomyopathy Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Mn)
12.1.4. North America Dilated Cardiomyopathy Market Size and Forecast, By Treatment Type, 2023-2034 (Revenue USD Mn)
12.1.5. North America Dilated Cardiomyopathy Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Mn)
12.1.6. North America Dilated Cardiomyopathy Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Mn)
12.2. U.S. Global Dilated Cardiomyopathy Market
12.2.1. U.S. Dilated Cardiomyopathy Market Size and Forecast, 2023-2034 (Revenue USD Mn)
12.2.2. U.S. Dilated Cardiomyopathy Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Mn)
12.2.3. U.S. Dilated Cardiomyopathy Market Size and Forecast, By Treatment Type, 2023-2034 (Revenue USD Mn)
12.2.4. U.S. Dilated Cardiomyopathy Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Mn)
12.2.5. U.S. Dilated Cardiomyopathy Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Mn)
12.3. Canada Global Dilated Cardiomyopathy Market
12.3.1. Canada Dilated Cardiomyopathy Market Size and Forecast, 2023-2034 (Revenue USD Mn)
12.3.2. Canada Dilated Cardiomyopathy Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Mn)
12.3.3. Canada Dilated Cardiomyopathy Market Size and Forecast, By Treatment Type, 2023-2034 (Revenue USD Mn)
12.3.4. Canada Dilated Cardiomyopathy Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Mn)
12.3.5. Canada Dilated Cardiomyopathy Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Mn)
13. Europe Global Dilated Cardiomyopathy Market
13.1. Europe Global Dilated Cardiomyopathy Market
13.1.1. Europe Dilated Cardiomyopathy Market Size and Forecast, 2023-2034 (Revenue USD Mn)
13.1.2. Europe Dilated Cardiomyopathy Market Size and Forecast, By Country, 2023-2034 (Revenue USD Mn)
13.1.3. Europe Dilated Cardiomyopathy Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Mn)
13.1.4. Europe Dilated Cardiomyopathy Market Size and Forecast, By Treatment Type, 2023-2034 (Revenue USD Mn)
13.1.5. Europe Dilated Cardiomyopathy Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Mn)
13.1.6. Europe Dilated Cardiomyopathy Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Mn)
13.2. Germany Global Dilated Cardiomyopathy Market
13.2.1. Germany Dilated Cardiomyopathy Market Size and Forecast, 2023-2034 (Revenue USD Mn)
13.2.2. Germany Dilated Cardiomyopathy Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Mn)
13.2.3. Germany Dilated Cardiomyopathy Market Size and Forecast, By Treatment Type, 2023-2034 (Revenue USD Mn)
13.2.4. Germany Dilated Cardiomyopathy Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Mn)
13.2.5. Germany Dilated Cardiomyopathy Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Mn)
13.3. UK Global Dilated Cardiomyopathy Market
13.3.1. UK Dilated Cardiomyopathy Market Size and Forecast, 2023-2034 (Revenue USD Mn)
13.3.2. UK Dilated Cardiomyopathy Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Mn)
13.3.3. UK Dilated Cardiomyopathy Market Size and Forecast, By Treatment Type, 2023-2034 (Revenue USD Mn)
13.3.4. UK Dilated Cardiomyopathy Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Mn)
13.3.5. UK Dilated Cardiomyopathy Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Mn)
13.4. France Global Dilated Cardiomyopathy Market
13.4.1. France Dilated Cardiomyopathy Market Size and Forecast, 2023-2034 (Revenue USD Mn)
13.4.2. France Dilated Cardiomyopathy Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Mn)
13.4.3. France Dilated Cardiomyopathy Market Size and Forecast, By Treatment Type, 2023-2034 (Revenue USD Mn)
13.4.4. France Dilated Cardiomyopathy Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Mn)
13.4.5. France Dilated Cardiomyopathy Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Mn)
13.5. Spain Global Dilated Cardiomyopathy Market
13.5.1. Spain Dilated Cardiomyopathy Market Size and Forecast, 2023-2034 (Revenue USD Mn)
13.5.2. Spain Dilated Cardiomyopathy Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Mn)
13.5.3. Spain Dilated Cardiomyopathy Market Size and Forecast, By Treatment Type, 2023-2034 (Revenue USD Mn)
13.5.4. Spain Dilated Cardiomyopathy Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Mn)
13.5.5. Spain Dilated Cardiomyopathy Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Mn)
13.6. Italy Global Dilated Cardiomyopathy Market
13.6.1. Italy Dilated Cardiomyopathy Market Size and Forecast, 2023-2034 (Revenue USD Mn)
13.6.2. Italy Dilated Cardiomyopathy Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Mn)
13.6.3. Italy Dilated Cardiomyopathy Market Size and Forecast, By Treatment Type, 2023-2034 (Revenue USD Mn)
13.6.4. Italy Dilated Cardiomyopathy Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Mn)
13.6.5. Italy Dilated Cardiomyopathy Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Mn)
13.7. Rest of Europe Global Dilated Cardiomyopathy Market
13.7.1. Rest of Europe Dilated Cardiomyopathy Market Size and Forecast, 2023-2034 (Revenue USD Mn)
13.7.2. Rest of Europe Dilated Cardiomyopathy Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Mn)
13.7.3. Rest of Europe Dilated Cardiomyopathy Market Size and Forecast, By Treatment Type, 2023-2034 (Revenue USD Mn)
13.7.4. Rest of Europe Dilated Cardiomyopathy Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Mn)
13.7.5. Rest of Europe Dilated Cardiomyopathy Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Mn)
14. Asia Pacific Global Dilated Cardiomyopathy Market
14.1. Asia Pacific Global Dilated Cardiomyopathy Market
14.1.1. Asia Pacific Dilated Cardiomyopathy Market Size and Forecast, 2023-2034 (Revenue USD Mn)
14.1.2. Asia Pacific Dilated Cardiomyopathy Market Size and Forecast, By Country, 2023-2034 (Revenue USD Mn)
14.1.3. Asia Pacific Dilated Cardiomyopathy Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Mn)
14.1.4. Asia Pacific Dilated Cardiomyopathy Market Size and Forecast, By Treatment Type, 2023-2034 (Revenue USD Mn)
14.1.5. Asia Pacific Dilated Cardiomyopathy Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Mn)
14.1.6. Asia Pacific Dilated Cardiomyopathy Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Mn)
14.2. Japan Global Dilated Cardiomyopathy Market
14.2.1. Japan Dilated Cardiomyopathy Market Size and Forecast, 2023-2034 (Revenue USD Mn)
14.2.2. Japan Dilated Cardiomyopathy Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Mn)
14.2.3. Japan Dilated Cardiomyopathy Market Size and Forecast, By Treatment Type, 2023-2034 (Revenue USD Mn)
14.2.4. Japan Dilated Cardiomyopathy Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Mn)
14.2.5. Japan Dilated Cardiomyopathy Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Mn)
14.3. China Global Dilated Cardiomyopathy Market
14.3.1. China Dilated Cardiomyopathy Market Size and Forecast, 2023-2034 (Revenue USD Mn)
14.3.2. China Dilated Cardiomyopathy Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Mn)
14.3.3. China Dilated Cardiomyopathy Market Size and Forecast, By Treatment Type, 2023-2034 (Revenue USD Mn)
14.3.4. China Dilated Cardiomyopathy Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Mn)
14.3.5. China Dilated Cardiomyopathy Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Mn)
14.4. India Global Dilated Cardiomyopathy Market
14.4.1. India Dilated Cardiomyopathy Market Size and Forecast, 2023-2034 (Revenue USD Mn)
14.4.2. India Dilated Cardiomyopathy Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Mn)
14.4.3. India Dilated Cardiomyopathy Market Size and Forecast, By Treatment Type, 2023-2034 (Revenue USD Mn)
14.4.4. India Dilated Cardiomyopathy Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Mn)
14.4.5. India Dilated Cardiomyopathy Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Mn)
14.5. South Korea Global Dilated Cardiomyopathy Market
14.5.1. South Korea Dilated Cardiomyopathy Market Size and Forecast, 2023-2034 (Revenue USD Mn)
14.5.2. South Korea Dilated Cardiomyopathy Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Mn)
14.5.3. South Korea Dilated Cardiomyopathy Market Size and Forecast, By Treatment Type, 2023-2034 (Revenue USD Mn)
14.5.4. South Korea Dilated Cardiomyopathy Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Mn)
14.5.5. South Korea Dilated Cardiomyopathy Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Mn)
14.6. Australia Global Dilated Cardiomyopathy Market
14.6.1. Australia Dilated Cardiomyopathy Market Size and Forecast, 2023-2034 (Revenue USD Mn)
14.6.2. Australia Dilated Cardiomyopathy Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Mn)
14.6.3. Australia Dilated Cardiomyopathy Market Size and Forecast, By Treatment Type, 2023-2034 (Revenue USD Mn)
14.6.4. Australia Dilated Cardiomyopathy Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Mn)
14.6.5. Australia Dilated Cardiomyopathy Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Mn)
14.7. Rest of Asia Pacific Global Dilated Cardiomyopathy Market
14.7.1. Rest of Asia Pacific Dilated Cardiomyopathy Market Size and Forecast, 2023-2034 (Revenue USD Mn)
14.7.2. Rest of Asia Pacific Dilated Cardiomyopathy Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Mn)
14.7.3. Rest of Asia Pacific Dilated Cardiomyopathy Market Size and Forecast, By Treatment Type, 2023-2034 (Revenue USD Mn)
14.7.4. Rest of Asia Pacific Dilated Cardiomyopathy Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Mn)
14.7.5. Rest of Asia Pacific Dilated Cardiomyopathy Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Mn)
15. Latin America Global Dilated Cardiomyopathy Market
15.1. Latin America Global Dilated Cardiomyopathy Market
15.1.1. Latin America Dilated Cardiomyopathy Market Size and Forecast, 2023-2034 (Revenue USD Mn)
15.1.2. Latin America Dilated Cardiomyopathy Market Size and Forecast, By Country, 2023-2034 (Revenue USD Mn)
15.1.3. Latin America Dilated Cardiomyopathy Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Mn)
15.1.4. Latin America Dilated Cardiomyopathy Market Size and Forecast, By Treatment Type, 2023-2034 (Revenue USD Mn)
15.1.5. Latin America Dilated Cardiomyopathy Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Mn)
15.1.6. Latin America Dilated Cardiomyopathy Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Mn)
15.2. Brazil Global Dilated Cardiomyopathy Market
15.2.1. Brazil Dilated Cardiomyopathy Market Size and Forecast, 2023-2034 (Revenue USD Mn)
15.2.2. Brazil Dilated Cardiomyopathy Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Mn)
15.2.3. Brazil Dilated Cardiomyopathy Market Size and Forecast, By Treatment Type, 2023-2034 (Revenue USD Mn)
15.2.4. Brazil Dilated Cardiomyopathy Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Mn)
15.2.5. Brazil Dilated Cardiomyopathy Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Mn)
15.3. Mexico Global Dilated Cardiomyopathy Market
15.3.1. Mexico Dilated Cardiomyopathy Market Size and Forecast, 2023-2034 (Revenue USD Mn)
15.3.2. Mexico Dilated Cardiomyopathy Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Mn)
15.3.3. Mexico Dilated Cardiomyopathy Market Size and Forecast, By Treatment Type, 2023-2034 (Revenue USD Mn)
15.3.4. Mexico Dilated Cardiomyopathy Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Mn)
15.3.5. Mexico Dilated Cardiomyopathy Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Mn)
15.4. Argentina Global Dilated Cardiomyopathy Market
15.4.1. Argentina Dilated Cardiomyopathy Market Size and Forecast, 2023-2034 (Revenue USD Mn)
15.4.2. Argentina Dilated Cardiomyopathy Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Mn)
15.4.3. Argentina Dilated Cardiomyopathy Market Size and Forecast, By Treatment Type, 2023-2034 (Revenue USD Mn)
15.4.4. Argentina Dilated Cardiomyopathy Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Mn)
15.4.5. Argentina Dilated Cardiomyopathy Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Mn)
15.5. Rest of Latin America Global Dilated Cardiomyopathy Market
15.5.1. Rest of Latin America Dilated Cardiomyopathy Market Size and Forecast, 2023-2034 (Revenue USD Mn)
15.5.2. Rest of Latin America Dilated Cardiomyopathy Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Mn)
15.5.3. Rest of Latin America Dilated Cardiomyopathy Market Size and Forecast, By Treatment Type, 2023-2034 (Revenue USD Mn)
15.5.4. Rest of Latin America Dilated Cardiomyopathy Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Mn)
15.5.5. Rest of Latin America Dilated Cardiomyopathy Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Mn)
16. MEA Global Dilated Cardiomyopathy Market
16.1. MEA Global Dilated Cardiomyopathy Market
16.1.1. MEA Dilated Cardiomyopathy Market Size and Forecast, 2023-2034 (Revenue USD Mn)
16.1.2. MEA Dilated Cardiomyopathy Market Size and Forecast, By Country, 2023-2034 (Revenue USD Mn)
16.1.3. MEA Dilated Cardiomyopathy Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Mn)
16.1.4. MEA Dilated Cardiomyopathy Market Size and Forecast, By Treatment Type, 2023-2034 (Revenue USD Mn)
16.1.5. MEA Dilated Cardiomyopathy Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Mn)
16.1.6. MEA Dilated Cardiomyopathy Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Mn)
16.2. GCC Global Dilated Cardiomyopathy Market
16.2.1. GCC Dilated Cardiomyopathy Market Size and Forecast, 2023-2034 (Revenue USD Mn)
16.2.2. GCC Dilated Cardiomyopathy Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Mn)
16.2.3. GCC Dilated Cardiomyopathy Market Size and Forecast, By Treatment Type, 2023-2034 (Revenue USD Mn)
16.2.4. GCC Dilated Cardiomyopathy Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Mn)
16.2.5. GCC Dilated Cardiomyopathy Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Mn)
16.3. South Africa Global Dilated Cardiomyopathy Market
16.3.1. South Africa Dilated Cardiomyopathy Market Size and Forecast, 2023-2034 (Revenue USD Mn)
16.3.2. South Africa Dilated Cardiomyopathy Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Mn)
16.3.3. South Africa Dilated Cardiomyopathy Market Size and Forecast, By Treatment Type, 2023-2034 (Revenue USD Mn)
16.3.4. South Africa Dilated Cardiomyopathy Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Mn)
16.3.5. South Africa Dilated Cardiomyopathy Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Mn)
16.4. Rest of MEA Global Dilated Cardiomyopathy Market
16.4.1. Rest of MEA Dilated Cardiomyopathy Market Size and Forecast, 2023-2034 (Revenue USD Mn)
16.4.2. Rest of MEA Dilated Cardiomyopathy Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Mn)
16.4.3. Rest of MEA Dilated Cardiomyopathy Market Size and Forecast, By Treatment Type, 2023-2034 (Revenue USD Mn)
16.4.4. Rest of MEA Dilated Cardiomyopathy Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Mn)
16.4.5. Rest of MEA Dilated Cardiomyopathy Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Mn)
17. Competitor Analysis
17.1. Company Market Share Analysis, 2023
17.2. Major Recent Developments
18. Company Profiles
18.1. Novartis AG
18.2. Pfizer Inc.
18.3. Bristol Myers Squibb Company
18.4. Merck & Co., Inc.
18.5. Johnson & Johnson
18.6. AstraZeneca PLC
18.7. Amgen Inc.
18.8. Bayer AG
18.9. Sanofi S.A.
18.10. Eli Lilly and Company
18.11. Abbott Laboratories
18.12. Boehringer Ingelheim International GmbH
18.13. GlaxoSmithKline plc
18.14. Mylan N.V. (now part of Viatris Inc.)
18.15. Roche Holding AG
19. Conclusion20. Recommendations

Companies Mentioned

  • AstraZeneca PLC
  • Amgen Inc.
  • Bayer AG
  • Sanofi S.A.
  • Eli Lilly and Company
  • Abbott Laboratories
  • Boehringer Ingelheim International GmbH
  • GlaxoSmithKline plc
  • Mylan N.V. (now part of Viatris Inc.)
  • Roche Holding AG.

Table Information